Clinical Trials | June 11, 2022
Sanyou Biopharmaceuticals launches Super-Trillion Antibody Libraries
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Objective tracking data combined with cohort data to drive medicine of the future
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
